These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2386980)

  • 1. Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
    Primus FJ; Pendurthi TK; Hutzell P; Kashmiri S; Slavin DC; Callahan R; Schlom J
    Cancer Immunol Immunother; 1990; 31(6):349-57. PubMed ID: 2386980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and characterization of a recombinant/chimeric B72.3 (human gamma 1).
    Hutzell P; Kashmiri S; Colcher D; Primus FJ; Hand PH; Roselli M; Finch M; Yarranton G; Bodmer M; Whittle N
    Cancer Res; 1991 Jan; 51(1):181-9. PubMed ID: 1988082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
    Pendurthi TK; Parker R; Schlom J; Primus FJ
    Int J Cancer; 1990 Dec; 46(6):1021-8. PubMed ID: 2123477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
    Colcher D; Milenic D; Roselli M; Raubitschek A; Yarranton G; King D; Adair J; Whittle N; Bodmer M; Schlom J
    Cancer Res; 1989 Apr; 49(7):1738-45. PubMed ID: 2924317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
    Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
    Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2.
    Morgan AC; Sullivan W; Graves S; Woodhouse CS
    Cancer Res; 1989 May; 49(10):2773-6. PubMed ID: 2785437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy.
    Masucci G; Wersäll P; Nielsen J; Nielsen HK; Wigzell H; Mellstedt H
    Hybridoma; 1989 Oct; 8(5):507-16. PubMed ID: 2807310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.
    Hand PH; Calvo B; Milenic D; Yokota T; Finch M; Snoy P; Garmestani K; Gansow O; Schlom J; Kashmiri SV
    Cancer Immunol Immunother; 1992; 35(3):165-74. PubMed ID: 1638552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
    Pendurthi TK; Schlom J; Primus FJ
    J Immunother (1991); 1991 Feb; 10(1):2-12. PubMed ID: 2012797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.
    Steplewski Z; Sun LK; Shearman CW; Ghrayeb J; Daddona P; Koprowski H
    Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4852-6. PubMed ID: 3387441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice.
    Watanabe M; Kubota T; Kitajima M; Hakomori S
    Cancer Immunol Immunother; 1993 Sep; 37(4):245-50. PubMed ID: 8348564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
    Tsang KY; Finch MD; Primus FJ; Schlom J
    Cancer Immunol Immunother; 1991; 34(1):9-16. PubMed ID: 1836975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model.
    Yamamoto T; Arakawa F; Nakamura K; Senba T; Tomita Y; Ikeda S; Kuroki M
    Cancer Immunol Immunother; 1999 Jul; 48(4):165-71. PubMed ID: 10431685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
    Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).
    Masucci G; Lindemalm C; Frödin JE; Hagström B; Mellstedt H
    Hybridoma; 1988 Oct; 7(5):429-40. PubMed ID: 3198133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
    Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
    J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
    Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
    Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin.
    Slavin-Chiorini DC; Horan Hand PH; Kashmiri SV; Calvo B; Zaremba S; Schlom J
    Int J Cancer; 1993 Jan; 53(1):97-103. PubMed ID: 8416208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.